|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BICDL2 |
Gene summary for BICDL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BICDL2 | Gene ID | 146439 |
| Gene name | BICD family like cargo adaptor 2 | |
| Gene Alias | BICDR-2 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A1A5D9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 146439 | BICDL2 | AEH-subject1 | Human | Endometrium | AEH | 2.89e-28 | 4.73e-01 | -0.3059 |
| 146439 | BICDL2 | AEH-subject2 | Human | Endometrium | AEH | 2.46e-28 | 6.16e-01 | -0.2525 |
| 146439 | BICDL2 | AEH-subject3 | Human | Endometrium | AEH | 8.38e-18 | 4.09e-01 | -0.2576 |
| 146439 | BICDL2 | AEH-subject4 | Human | Endometrium | AEH | 1.11e-12 | 3.32e-01 | -0.2657 |
| 146439 | BICDL2 | AEH-subject5 | Human | Endometrium | AEH | 8.49e-10 | 2.07e-01 | -0.2953 |
| 146439 | BICDL2 | EEC-subject1 | Human | Endometrium | EEC | 4.06e-07 | 1.98e-01 | -0.2682 |
| 146439 | BICDL2 | EEC-subject2 | Human | Endometrium | EEC | 1.45e-37 | 7.25e-01 | -0.2607 |
| 146439 | BICDL2 | EEC-subject4 | Human | Endometrium | EEC | 7.12e-13 | 2.96e-01 | -0.2571 |
| 146439 | BICDL2 | EEC-subject5 | Human | Endometrium | EEC | 4.35e-17 | 3.13e-01 | -0.249 |
| 146439 | BICDL2 | GSM5276935 | Human | Endometrium | EEC | 2.24e-16 | 3.09e-01 | -0.123 |
| 146439 | BICDL2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.01e-09 | 3.16e-01 | -0.1934 |
| 146439 | BICDL2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.51e-03 | 2.09e-01 | -0.1917 |
| 146439 | BICDL2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.47e-05 | 2.95e-01 | -0.1916 |
| 146439 | BICDL2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 3.29e-02 | 1.12e-01 | -0.1269 |
| 146439 | BICDL2 | male-WTA | Human | Thyroid | PTC | 1.29e-07 | 1.25e-01 | 0.1037 |
| 146439 | BICDL2 | PTC01 | Human | Thyroid | PTC | 4.25e-14 | 2.34e-01 | 0.1899 |
| 146439 | BICDL2 | PTC03 | Human | Thyroid | PTC | 4.84e-06 | 2.83e-01 | 0.1784 |
| 146439 | BICDL2 | PTC04 | Human | Thyroid | PTC | 4.42e-19 | 2.97e-01 | 0.1927 |
| 146439 | BICDL2 | PTC05 | Human | Thyroid | PTC | 1.80e-14 | 5.48e-01 | 0.2065 |
| 146439 | BICDL2 | PTC06 | Human | Thyroid | PTC | 1.32e-26 | 6.70e-01 | 0.2057 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00516568 | Endometrium | AEH | establishment of organelle localization | 77/2100 | 390/18723 | 4.89e-07 | 1.94e-05 | 77 |
| GO:00307058 | Endometrium | AEH | cytoskeleton-dependent intracellular transport | 38/2100 | 195/18723 | 4.72e-04 | 4.91e-03 | 38 |
| GO:00516507 | Endometrium | AEH | establishment of vesicle localization | 32/2100 | 161/18723 | 8.99e-04 | 8.24e-03 | 32 |
| GO:00516487 | Endometrium | AEH | vesicle localization | 32/2100 | 177/18723 | 4.33e-03 | 2.86e-02 | 32 |
| GO:005165613 | Endometrium | EEC | establishment of organelle localization | 75/2168 | 390/18723 | 6.23e-06 | 1.49e-04 | 75 |
| GO:003070514 | Endometrium | EEC | cytoskeleton-dependent intracellular transport | 39/2168 | 195/18723 | 4.40e-04 | 4.58e-03 | 39 |
| GO:005165013 | Endometrium | EEC | establishment of vesicle localization | 31/2168 | 161/18723 | 2.99e-03 | 2.10e-02 | 31 |
| GO:005165620 | Thyroid | PTC | establishment of organelle localization | 193/5968 | 390/18723 | 2.21e-13 | 1.15e-11 | 193 |
| GO:0030705111 | Thyroid | PTC | cytoskeleton-dependent intracellular transport | 104/5968 | 195/18723 | 3.87e-10 | 1.24e-08 | 104 |
| GO:005165019 | Thyroid | PTC | establishment of vesicle localization | 89/5968 | 161/18723 | 6.38e-10 | 1.97e-08 | 89 |
| GO:005164817 | Thyroid | PTC | vesicle localization | 94/5968 | 177/18723 | 3.54e-09 | 9.45e-08 | 94 |
| GO:00109709 | Thyroid | PTC | transport along microtubule | 80/5968 | 155/18723 | 2.48e-07 | 4.32e-06 | 80 |
| GO:00723848 | Thyroid | PTC | organelle transport along microtubule | 47/5968 | 85/18723 | 6.61e-06 | 7.83e-05 | 47 |
| GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
| GO:00995187 | Thyroid | PTC | vesicle cytoskeletal trafficking | 38/5968 | 73/18723 | 2.69e-04 | 1.91e-03 | 38 |
| GO:00474963 | Thyroid | PTC | vesicle transport along microtubule | 24/5968 | 47/18723 | 4.79e-03 | 2.24e-02 | 24 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa048144 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa0481411 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa048142 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
| hsa048143 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BICDL2 | SNV | Missense_Mutation | rs779848180 | c.355N>A | p.Val119Met | p.V119M | A1A5D9 | protein_coding | deleterious(0.05) | benign(0.035) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
| BICDL2 | SNV | Missense_Mutation | c.1225G>A | p.Glu409Lys | p.E409K | A1A5D9 | protein_coding | tolerated(0.05) | benign(0.288) | TCGA-C5-A7UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| BICDL2 | SNV | Missense_Mutation | c.337G>A | p.Glu113Lys | p.E113K | A1A5D9 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-EA-A3HR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| BICDL2 | SNV | Missense_Mutation | c.1031N>G | p.Pro344Arg | p.P344R | A1A5D9 | protein_coding | tolerated(0.16) | probably_damaging(0.931) | TCGA-A6-2671-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Other, specify in notesProtocol AMG 20060464 | study | PD | |
| BICDL2 | SNV | Missense_Mutation | c.742C>T | p.Arg248Trp | p.R248W | A1A5D9 | protein_coding | deleterious(0.01) | possibly_damaging(0.805) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| BICDL2 | SNV | Missense_Mutation | rs764724643 | c.590N>T | p.Thr197Met | p.T197M | A1A5D9 | protein_coding | tolerated(0.13) | benign(0.015) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| BICDL2 | SNV | Missense_Mutation | rs766741399 | c.662G>A | p.Arg221Gln | p.R221Q | A1A5D9 | protein_coding | tolerated(0.11) | benign(0.06) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BICDL2 | SNV | Missense_Mutation | c.230A>C | p.Glu77Ala | p.E77A | A1A5D9 | protein_coding | deleterious(0.01) | benign(0.35) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| BICDL2 | insertion | Frame_Shift_Ins | rs769749885 | c.1032_1033insC | p.Lys345GlnfsTer25 | p.K345Qfs*25 | A1A5D9 | protein_coding | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| BICDL2 | SNV | Missense_Mutation | rs554176594 | c.737N>A | p.Arg246Gln | p.R246Q | A1A5D9 | protein_coding | deleterious(0.02) | possibly_damaging(0.795) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |